445 results on '"Bavbek, Sevim"'
Search Results
2. Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study
3. Comparison of two diagnostic criteria in the diagnosis of anaphylaxis in a tertiary adult allergy clinic
4. Placebo, Nocebo, and Patient-Reported Outcome Measures in Drug Allergy
5. Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study
6. Rapid drug desensitization with platin-based chemotherapy: Analysis of risk factors for breakthrough reactions
7. Hypersensitivity reactions to proton pump inhibitors. An EAACI position paper
8. Role of Skin Tests in the Diagnosis of Immediate Hypersensitivity Reactions to Taxanes: Results of a Multicenter Study
9. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial
10. Hypersensitivity reactions to proton pump inhibitors. An EAACI position paper.
11. Apples and pears serve the same purpose: Better diagnosis for anaphylaxis
12. Real-world patient-level cost-effectiveness analysis of omalizumab in patients with severe allergic asthma
13. Multi-country self-controlled study of exacerbation rates in severe asthma patients treated with mepolizumab: NEST interim analysis
14. Hypersensitivity reactions to nonsteroidal anti-inflammatory drugs in adults
15. Omalizumab in the treatment of eosinophilic granulomatosis with polyangiitis (EGPA): single-center experience in 18 cases
16. Subcutaneous Injectable Drugs Hypersensitivity and Desensitization: Insulin and Monoclonal Antibodies
17. Real-world patient-level cost-effectiveness analysis of omalizumab in patients with severe allergic asthma treated in four major medical centers in Turkey
18. Physicians' preference for controller medication in mild persistent asthma
19. Stepwise Approach in Asthma Revisited 2023: Expert Panel Opinion of Turkish Guideline of Asthma Diagnosis and Management Group.
20. Turkish version of the Drug Hypersensitivity Quality of Life Questionnaire: assessment of reliability and validity
21. Field sting reactions in patients receiving Hymenoptera venom immunotherapy: Real-life experience.
22. Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study
23. Anaphylaxis is rare due to CoronaVac in a population of healthcare workers
24. Incidence and clinical course of COVID-19 in patients using omalizumab for chronic spontaneous urticaria and/or severe allergic asthma and using mepolizumab for severe eosinophilic asthma: A single center real life experience
25. Biologics for the treatment of severe asthma: Current status report 2023.
26. The profile of severe asthmatics: Results from a specialized asthma clinic.
27. Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study
28. Allergies and COVID-19 vaccines : An ENDA/EAACI Position paper
29. Allergies and COVID-19 vaccines:An ENDA/EAACI Position paper
30. Eosinophilic granulomatosis with polyangitis: A new target for biologicals
31. A Patient with Local Hypersensitivity Reactions to Three TNF-α Inhibitors and Local/Systemic Hypersensitivity Reactions to Tocilizumab: Desensitization to Tocilizumab
32. Allergies and COVID‐19 vaccines: An ENDA/EAACI Position paper
33. Anwendung von Biologika bei allergischen und Typ-2-entzündlichen Erkrankungen in der aktuellen Covid-19-Pandemiea, b, c
34. Allergen-specific immunotherapy practices and course of coronavirus disease 2019 (COVID-19) in patients during COVID-19
35. Effectiveness of Low-Dose Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA): A Real-Life Experience
36. Mepolizumab Is an Effective Option in Severe Eosinophilic Asthma Regardless of Baseline Features: Single-Center Real-Life Data
37. Hypersensitivity reactions to chemotherapy: an EAACI Position Paper
38. Country-based report: the safety of omalizumab treatment in pregnant patients with asthma
39. Sabit doz inhale kortikosteroid, uzun etkili beta-2 agonist ve uzun etkili muskarinik reseptör antagonisti (İKS/LABA/LAMA) kombinasyonunun astım tedavisindeki yeri
40. Effect of drug desensitization on drug hypersensitivity-related quality of life
41. Incidence and clinical course of COVID-19 in patients using omalizumab for chronic spontaneous urticaria and/or severe allergic asthma and using mepolizumab for severe eosinophilic asthma: A single center real life experience.
42. Prevalence of hypersensitivity reactions against drugs among adult population in Turkey: a self-reported survey
43. Hypersensitivity reactions to biologicals: An EAACI position paper
44. COVID-19-vaccination in patients receiving allergen immunotherapy (AIT) or biologics - EAACI recommendations
45. GINA 2019 - step 1 and 2 treatment in asthma: Updates with reasons behind
46. Practice parameters for diagnosing and managing iodinated contrast media hypersensitivity
47. Change in allergy practice during the COVID-19 pandemic
48. Microbiota- the unseen players in adult asthmatic airways
49. ABPA’lı hastalarda biyolojik tedaviler
50. Mepolizumab Is an Effective Option in Severe Eosinophilic Asthma Regardless of Baseline Features: Single-Center Real-Life Data.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.